
|Articles|August 1, 2004
Supplements and Featured Publications
- Newsletter - Inflammation, Metabolic Syndrome, and CV Risk Reduction
- Volume 10
- Issue 2 Metab
CE / CME
Advertisement
Articles in this issue
over 21 years ago
Commentaryover 21 years ago
Post Testover 21 years ago
Faculty Disclosure Statementover 21 years ago
Metabolic syndrome: A new target of therapy?Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
3
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
4
Orlowski Calls Linvoseltamab Results “the Best Single-Agent Data Ever in the History of Myeloma”
5









































